BIOKIN PHARMACEUTICAL(SH:688506) Xin Lang Cai Jing·2025-10-31 02:17Core Viewpoint - Baili Tianheng Pharmaceutical Co., Ltd. has seen a stock price increase of 5.13% to 353.77 CNY per share, with a total market capitalization of 146.06 billion CNY as of October 31 [1] Company Overview - Baili Tianheng was established on August 17, 2006, and went public on January 6, 2023. The company is located in Chengdu, Sichuan Province, and focuses on the research, production, and sales of pharmaceuticals [1] - The company's main business revenue is composed of 99.57% recognized at a specific point in time and 0.43% recognized over a period [1] Fund Holdings - According to data, one fund under Industrial Bank holds a significant position in Baili Tianheng. The Industrial Bank Science and Technology Price ETF (589050) held 1,400 shares in the third quarter, accounting for 1.41% of the fund's net value, making it the sixth-largest holding [2] - The estimated floating profit from this holding is approximately 24,200 CNY as of the report date [2] Fund Performance - The Industrial Bank Science and Technology Price ETF (589050) was established on July 30, 2025, with a current scale of 37.24 million CNY and a cumulative return of 17.49% since inception [3] - The fund managers, Xu Chengcheng and Zhang Shiyue, have significant experience, with Xu having managed assets totaling 1.135 billion CNY and achieving a best return of 769.46% during his tenure [4] - Zhang has managed assets of 765 million CNY, with a best return of 47.72% during his tenure [4]